Skip to main content

The bid comes a week after the U.S. Supreme Court upheld subsidies for individuals under President Barack Obama’s signature healthcare law, keeping a large chunk of patients intact under the Medicare and Medicaid programs

Andrei Tchernov/iStockphoto

PointClickCare, a Canadian health-care software provider, filed for an initial public offering in the U.S. and plans to do the same in Canada.

The Mississauga, Ontario-based company plans to list on the Nasdaq Stock Market under the stock symbol PCLK, and intends to go public on the Toronto Stock Exchange as PCC, according to the prospectus and a statement filed Thursday.

PointClickCare is one of a wave of Canadian tech companies beginning to tap public markets. E-commerce software maker Shopify Inc. has increased about 60 per cent in U.S. trading since its listing in May. Hootsuite Media Inc. has said it could go public by the end of 2016 and Vision Critical Communications Inc. is weighing the sale of part of its business ahead of a possible IPO early next year, according to people familiar with the process.

Story continues below advertisement

PointClickCare's IPO is being arranged by JPMorgan Chase & Co., Goldman Sachs Group, Royal Bank of Canada, William Blair & Co. and Canaccord Genuity Group Inc.

The company plans to use the proceeds for working capital and general proceeds, to repay debt and cover a special dividend to shareholders of about $17.5-million before the close of the offering.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies